Project focuses on tumor-targeted DDS and dual-target 인기있는바카라사이트NK technology to overcome challenges in solid tumors
[By Yu, Suin] Vaxcellbio, a leading developer of cancer immunotherapies, announced on Thursday that it has been selected as the lead organization for a new national bio R&D project under the Ministry of Trade, Industry and Energy (MOTIE)’s Bio-Industry Technology Development Program. The project, valued at KRW 8.6 billion (approximately USD 6.2 million), will be carried out over the next five years.
The official title of the project is “Development of Manufacturing Technologies for Next-Generation Advanced Biologics Based on Fusion CAR-NK Immunotherapies Utilizing Precision Drug Delivery Systems.” Vaxcellbio will sign a formal agreement in the coming days with the Korea Evaluation Institute of Industrial Technology (KEIT) and officially launch the project.
In collaboration with CNCure, a partner company specializing in microbial-based drug delivery technologies, Vaxcellbio will develop next-generation cell therapies targeting solid tumors—an area of high unmet medical need.
The core objective of this initiative is to create an innovative, off-the-shelf 인기있는바카라사이트NK platform that maximizes tumor infiltration and antitumor efficacy by combining:
a tumor microenvironment-specific microbial Drug Delivery System (DDS), and
a dual-targeting, immune-enhanced 인기있는바카라사이트NK technology.
While conventional CAR-based 인기있는바카라사이트 therapies have shown significant success in hematologic cancers, they have faced critical challenges in treating solid tumors due to immune suppression and poor tumor penetration. This project is strategically designed to overcome such hurdles and offer a new paradigm in solid tumor treatment.
Throughout the project, 인기있는바카라사이트 will also establish GMP-compliant manufacturing processes and quality control systems. Preclinical studies will be conducted to evaluate safety and efficacy, paving the way for future clinical trials and commercial development.
CEO Je-Jung Lee commented, “This national project award serves as an official recognition of Vaxcellbio’s technological capabilities and growth potential. By integrating precision drug delivery with our advanced CAR-NK platform, we aim to overcome the limitations of current treatments for solid tumors and deliver a first-in-class therapeutic innovation with global competitiveness.”
He further added, “Beyond R&D, this initiative will serve as a launchpad for Vaxcellbio’s broader leadership in the next-generation cell therapy industry—enabling global clinical entry, technology licensing, and expanded strategic collaborations.”
인기있는바카라사이트 continues to strengthen its IP portfolio across key global markets, with multiple patents already granted based on its proprietary cancer immunotherapy platforms. The company is accelerating international patent filings, particularly in CAR- and NK-related core technologies, and is preparing for active engagement in global markets through licensing and co-development partnerships.
인기있는바카라사이트 has secured a KRW 8.6 billion (approximately USD 6.2 million) national R&D project from the Ministry of Trade, Industry and Energy (MOTIE) as the lead partner to develop next-generation CAR-NK cell therapies for solid tumors, integrating precision drug delivery systems and dual-targeting capabilities.
The company will collaborate with CNCure, a specialist in microbial-based drug delivery, to engineer a tumor microenvironment-specific DDS and an immune-enhanced 인기있는바카라사이트NK platform, aiming to create an off-the-shelf immunotherapy with superior tumor infiltration and antitumor efficacy.
This project positions 인기있는바카라사이트 as a frontrunner in the global cell therapy market, with plans to establish GMP-compliant manufacturing, conduct preclinical studies, and pursue international clinical trials, technology licensing, and strategic collaborations.
CEO Je-Jung Lee said, “This national project award serves as an official recognition of Vaxcellbio’s technological capabilities and growth potential. By integrating precision drug delivery with our advanced CAR-NK platform, we aim to overcome the limitations of current treatments for solid tumors and deliver a first-in-class therapeutic innovation with global competitiveness.”